首页|华蟾素调控PI3K/AKT通路逆转卵巢癌A2780/DDP细胞顺铂耐药的作用机制

华蟾素调控PI3K/AKT通路逆转卵巢癌A2780/DDP细胞顺铂耐药的作用机制

Mechanism of cinobufagin regulating PI3K/AKT signaling pathway to reverse cisplatin resistance in ovarian cancer A2780/DDP cells

扫码查看
目的 研究华蟾素(CBG)对人卵巢癌细胞顺铂耐药的逆转作用和机制.方法 A2780 细胞株及其顺铂耐药细胞株A2780/DDP是临床常见的卵巢癌细胞,故选择这两种细胞株作为研究对象.通过CCK-8 法检测细胞活力,平板克隆和5-乙炔基-2′脱氧尿嘧啶核苷(EdU)实验检测细胞的增殖能力,赫斯特染色(Hoechst)法观察细胞凋亡情况,细胞划痕实验和 Transwell 实验评估细胞的迁移和侵袭能力,Western blot和定量逆转录PCR(RT-qPCR)法检测磷脂酰肌醇3-激酶/蛋白激酶(PI3K/AKT)信号通路和上皮-间质转化(EMT)的相关蛋白和 mRNA 的表达差异.结果 与A2780 细胞相比,A2780/DDP 细胞的耐药指数分别约为5.636、5.864、5.695,采用CBG(2、4、6 mg/ml)处理 A2780/DDP耐药细胞后,逆转耐药指数分别为1.617、2.570、3.461.CBG呈浓度依赖性地上调细胞凋亡水平、抑制细胞的增殖、迁移和侵袭能力(P<0.05).Western blot 结果显示:与A2780 细胞相比,对照组(A2780/DDP)细胞中P-PI3K/PI3K和P-AKT/AKT的蛋白水平相对比值以及 N 钙黏蛋白(N-cadherin)、波形蛋白(Vimentin)、蜗牛蛋白(Snail)的蛋白表达更高,E钙黏蛋白(E-cadherin)蛋白表达更低(tP-PI3K/PI3K=8.115,tP-AKT/AKT=17.62、tN-cadherin=6.126、tVimentin=4.001、tSnail=17.333、tE-cadherin=4.620,P<0.01);随着CBG剂量升高,耐药细胞中的P-PI3K、P-AKT、N-cadherin、Vimentin、Snail的蛋白表达水平降低,而 E-cadherin的蛋白表达量增加(FP-PI3K=268.5、FP-AKT=190.5、FN-cadherin=24.02、FVimentin=57.65、FSnail=87.24、FE-cadherin=135.8,P<0.05).RT-qPCR结果显示:随着 CBG 浓度增加,PI3K、AKT、N-cadherin、Vimentin、Snail的mRNA表达水平随之降低,相反E-cadherin的mRNA表达水平逐渐升高(FPI3K=101.1、FAKT=558.3、FN-cadherin=86.97、FVimentin=105.9、FSnail=85.71、FE-cadherin=80.96,P<0.01).结论 CBG具有逆转卵巢癌A2780/DDP细胞株顺铂耐药的作用,其机制可能与CBG调控PI3K/AKT信号通路和抑制EMT发生有关.
Objective To investigate the reversal effect and mechanism of cinobufagin(CBG)on cisplatin resist-ance in human ovarian cancer cells.Methods A2780 cell line and its cisplatin-resistant cell line A2780/DDP are common ovarian cancer cells in clinic,so these two cell lines were selected as the research objects.The cell viabil-ity was detected by cell Counting Kit-8(CCK-8)assay,and the cell proliferation ability was detected by plate clo-ning and 5-ethynyl-2′-deoxyuridine(EdU)assay.Hoechst staining was used to observe cell apoptosis.Cell scratch test and Transwell test were used to evaluate cell migration and invasion ability.Western blot and quantitative reverse transcription PCR(RT-qPCR)were used to detect the protein and mRNA expressions of phosphatidylinosi-tol 3-kinase/protein kinase(PI3K/AKT)signaling pathway and epithelial-mesenchymal transition(EMT).Re-sults Compared with A2780 cells,the drug resistance indexes of A2780/DDP cells were 5.636,5.864,5.695,respectively.After treatment of A2780/DDP cells with CBG(2,4,6 mg/ml),the reversal resistance indexes were 1.617,2.570,3.461,respectively.CBG treatment significantly increased the level of apoptosis and inhibi-ted the proliferation,migration and invasion of the cells in a concentration-dependent manner(P<0.05).Western blot results showed that compared with A2780 cells,the relative ratio of P-PI3K/PI3K and P-AKT/AKT protein levels,as well as the protein expression of N-cadherin,Vimentin,and Snail were higher in the control group(A2780/DDP)cells,while the protein expression of E-cadherin was lower(tP-PI3K/PI3K=8.115,tP-AKT/AKT=17.62,tN-cadherin=6.126,tVimentin=4.001,tSnail=17.333,tE-cadherin=4.620,P<0.01);As the dose of CBG increased,the protein expression levels of P-PI3K,P-AKT,N-cadherin,Vimentin,and Snail in drug-resistant cells de-creased,while the protein expression level of E-cadherin increased(FP-PI3K=268.5,FP-AKT=190.5,FN-cadherin=24.02,FVimentin=57.65,FSnail=87.24,FE-cadherin=135.8,P<0.05).qRT-PCR results showed that with the in-crease of CBG concentration,the mRNA expression levels of PI3K,AKT,N-cadherin,Vimentin and Snail de-creased,while the mRNA expression level of E-cadherin gradually increased(FPI3K=101.1,FAKT=558.3,FN-cadherin=86.97,FVimentin=105.9,FSnail=85.71,FE-cadherin=80.96,P<0.01).Conclusion CBG can reverse cisplatin resistance of ovarian cancer A2780/DDP cell line,and its mechanism may be related to the regulation of PI3K/AKT signaling pathway and inhibition of EMT by CBG.

cinobufaginovarian cancercisplatin resistancereversal of drug resistancePI3K/AKTEMTmecha-nism of action

舒美玲、吴悦、叶映泉、张爽爽、张梅

展开 >

安徽医科大学中西医结合临床医学系,合肥 230032

安徽医科大学第一附属医院中西医结合肿瘤科,合肥 230022

华蟾素 卵巢癌 顺铂耐药 逆转耐药 PI3K/AKT 上皮间质转化 作用机制

安徽省重大疑难疾病(卵巢癌)中西医协同攻关项目(2021)安徽省"115"产业创新团队项目(第十三批)

皖中医药发展秘[2022]70号

2024

安徽医科大学学报
安徽医科大学

安徽医科大学学报

CSTPCD北大核心
影响因子:1.095
ISSN:1000-1492
年,卷(期):2024.59(4)
  • 14